{"transactions":[{"id":687722,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2026-08-13T20:15:33.000Z","date":"2026-08-12","kind":"sale","planned":true,"acquired":false,"shares":8506,"price":25,"value":212650.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025."}],"balance_after":41931,"source":{"system":"sec-edgar","filing":"0000905148-26-003620","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514826003620/form4.xml","form_type":"4"}},{"id":727429,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2026-06-24T20:05:11.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":7040,"price":18.09,"value":127353.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025."}],"balance_after":50437,"source":{"system":"sec-edgar","filing":"0000905148-26-003077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514826003077/form4.xml","form_type":"4"}},{"id":730069,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2026-06-22T20:08:21.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":22371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date."}],"balance_after":57477,"source":{"system":"sec-edgar","filing":"0000905148-26-003031","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514826003031/form4.xml","form_type":"4"}},{"id":1103480,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2025-06-23T20:10:46.000Z","date":"2025-06-20","kind":"sale","planned":true,"acquired":false,"shares":13814,"price":35.67,"value":492745.38,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":35106,"source":{"system":"sec-edgar","filing":"0000905148-25-002215","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514825002215/form4.xml","form_type":"4"}},{"id":1103479,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2025-06-23T20:10:46.000Z","date":"2025-06-18","kind":"grant","planned":true,"acquired":true,"shares":10831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted shares that vest in full on June 18, 2026, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date."}],"balance_after":48920,"source":{"system":"sec-edgar","filing":"0000905148-25-002215","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514825002215/form4.xml","form_type":"4"}},{"id":1226516,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2025-03-04T22:11:30.000Z","date":"2025-02-28","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":32.98,"value":494700.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2024."}],"balance_after":38089,"source":{"system":"sec-edgar","filing":"0000905148-25-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514825000827/form4.xml","form_type":"4"}},{"id":1459331,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2024-07-03T18:04:24.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":18.04,"value":1804.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024."}],"balance_after":53089,"source":{"system":"sec-edgar","filing":"0000905148-24-001839","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514824001839/form4.xml","form_type":"4"}},{"id":1459330,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2024-07-03T18:04:24.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":10297,"price":17.3139,"value":178281.2283,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects a weighted average sale price of $17.3139 per share, at prices ranging from $17.02 to $17.96 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":53189,"source":{"system":"sec-edgar","filing":"0000905148-24-001839","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514824001839/form4.xml","form_type":"4"}},{"id":1472805,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2024-06-20T21:00:20.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":21253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted shares that vest in full on June 18, 2025, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date."}],"balance_after":63486,"source":{"system":"sec-edgar","filing":"0000905148-24-001748","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000090514824001748/form4.xml","form_type":"4"}},{"id":1760470,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-10-13T22:56:56.000Z","date":"2023-10-13","kind":"sale","planned":true,"acquired":false,"shares":7965,"price":0.8508,"value":6776.622,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a trading plan intended to comply with Rule 10b5-1(c) and adopted by the Reporting Person on June 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.84 to $0.8717, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":53521,"source":{"system":"sec-edgar","filing":"0001013762-23-003901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000101376223003901/ownership.xml","form_type":"4"}},{"id":1840828,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2023-06-30T20:05:50.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":18903,"price":26.45,"value":499984.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."}],"balance_after":42233,"source":{"system":"sec-edgar","filing":"0000950170-23-031097","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000095017023031097/ownership.xml","form_type":"4"}},{"id":1861798,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:42:24.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047568","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390023047568/ownership.xml","form_type":"4"}},{"id":1919372,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-04-14T20:14:22.000Z","date":"2023-04-13","kind":"sale","planned":false,"acquired":false,"shares":8500,"price":1.44,"value":12240.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":61486,"source":{"system":"sec-edgar","filing":"0001213900-23-029888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390023029888/ownership.xml","form_type":"4"}},{"id":1965079,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2023-03-07T21:05:34.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":5434,"price":38.31,"value":208176.54,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction was effected pursuant to a sale plan adopted by the Reporting Person, dated 12/30/2022, that expires on 05/31/2023 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934."}],"balance_after":23330,"source":{"system":"sec-edgar","filing":"0000899243-23-007333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000089924323007333/doc4.xml","form_type":"4"}},{"id":2137512,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2022-10-13T23:58:35.000Z","date":"2022-10-12","kind":"grant","acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":69986,"source":{"system":"sec-edgar","filing":"0001213900-22-063936","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390022063936/ownership.xml","form_type":"4"}},{"id":2219986,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2022-06-28T20:01:39.000Z","date":"2022-06-27","kind":"sale","acquired":false,"shares":24743,"price":2.0775,"value":51403.5825,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.86 to $2.30, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":40486,"source":{"system":"sec-edgar","filing":"0001213900-22-035570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390022035570/ownership.xml","form_type":"4"}},{"id":2219985,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2022-06-28T20:01:39.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":24743,"price":2.022,"value":50030.346,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.88 to $2.24, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":65229,"source":{"system":"sec-edgar","filing":"0001213900-22-035570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390022035570/ownership.xml","form_type":"4"}},{"id":2319774,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T22:01:02.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/12th of the shares subject to the option shall vest on April 15, 2022, and 1/12th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive"}],"balance_after":100000,"derivative":{"exercise_price":3.54,"expiration_date":"2032-03-21","underlying":"Voting Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-22-014562","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390022014562/ownership.xml","form_type":"4"}},{"id":2319773,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T22:01:02.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":89972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares subject to the option vested on March 21, 2022, and 1/4th of the shares subject to the option shall vest on each of March 24, 2022, September 24, 2022 and March 24, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":89972,"derivative":{"exercise_price":3.54,"expiration_date":"2032-03-21","underlying":"Voting Common Stock","underlying_shares":89972},"source":{"system":"sec-edgar","filing":"0001213900-22-014562","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390022014562/ownership.xml","form_type":"4"}},{"id":2319772,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T22:01:02.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":7500,"derivative":{"exercise_price":3.54,"expiration_date":"2032-03-21","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-22-014562","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390022014562/ownership.xml","form_type":"4"}},{"id":2319771,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2022-03-23T22:01:02.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":89972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of June 24, 2022 and June 27, 2022, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":89972,"source":{"system":"sec-edgar","filing":"0001213900-22-014562","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390022014562/ownership.xml","form_type":"4"}},{"id":2397130,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-02-14T21:05:52.000Z","date":"2021-01-05","kind":"tax_withholding","acquired":false,"shares":5350,"price":129.14,"value":690899.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition of shares to cover taxes. The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated December 4, 2020 and which expired January 5, 2021, and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934."}],"balance_after":22927,"source":{"system":"sec-edgar","filing":"0000899243-22-006141","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000089924322006141/doc5.xml","form_type":"5"}},{"id":2428552,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-01-21T22:10:50.000Z","date":"2022-01-20","kind":"sale","acquired":false,"shares":1926,"price":53.4,"value":102848.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated September 1, 2021, expires January 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934."}],"balance_after":34114,"source":{"system":"sec-edgar","filing":"0001567619-22-001445","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000156761922001445/doc1.xml","form_type":"4"}},{"id":2447467,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-01-05T02:12:01.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":7763,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36040,"source":{"system":"sec-edgar","filing":"0001567619-22-000397","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000156761922000397/doc1.xml","form_type":"4"}},{"id":2892211,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T19:06:52.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":43056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The option vests in three annual installments after December 4, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in three annual installments after December 4, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":13.67,"expiration_date":"2028-12-04","underlying":"Common Stock","underlying_shares":43056},"source":{"system":"sec-edgar","filing":"0000899243-21-003644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003644/doc4.xml","form_type":"4"}},{"id":2892210,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T19:06:52.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":21528,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option vests in a single installment on May 27, 2021.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in a single installment on May 27, 2021.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":30.87,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":21528},"source":{"system":"sec-edgar","filing":"0000899243-21-003644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003644/doc4.xml","form_type":"4"}},{"id":2892209,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T19:06:52.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":21528,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) The option vests in a single installment on May 27, 2021.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from footnote 1) The option vests in a single installment on May 27, 2021.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":48.51,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":21528},"source":{"system":"sec-edgar","filing":"0000899243-21-003644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003644/doc4.xml","form_type":"4"}},{"id":2901605,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-01-20T23:36:36.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":3852,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28277,"source":{"system":"sec-edgar","filing":"0000899243-21-002543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000089924321002543/doc4.xml","form_type":"4"}},{"id":3130765,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-29T16:05:18.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":21528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended)."}],"balance_after":21528,"derivative":{"exercise_price":48.51,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":21528},"source":{"system":"sec-edgar","filing":"0000899243-20-014538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320014538/doc4.xml","form_type":"4"}},{"id":3491495,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-13T21:23:48.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":21528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on June 12, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended)."}],"balance_after":21528,"derivative":{"exercise_price":30.87,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":21528},"source":{"system":"sec-edgar","filing":"0000899243-19-016951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924319016951/doc4.xml","form_type":"4"}},{"id":3739595,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-07T20:42:55.000Z","date":"2018-12-04","kind":"grant","acquired":true,"shares":43056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Issuer's board of directors on December 4, 2018, and is subject to cancellation if the Issuer's shareholders do not approve an increase to the share reserve of the stock option plan under which the option was granted by December 4, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 43,056 stock options (the \"Grant\") on December 4, 2018.  The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following December 4, 2018 subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":43056,"derivative":{"exercise_price":13.67,"expiration_date":"2028-12-04","underlying":"Common Stock","underlying_shares":43056},"source":{"system":"sec-edgar","filing":"0000899243-18-030438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924318030438/doc4.xml","form_type":"4"}},{"id":3831431,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-08-28T18:13:31.000Z","date":"2018-08-23","kind":"tax_withholding","acquired":false,"shares":17587,"price":26.05,"value":458141.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":204448,"source":{"system":"sec-edgar","filing":"0001209191-18-048736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118048736/doc4.xml","form_type":"4"}},{"id":3831430,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-08-28T18:13:31.000Z","date":"2018-07-28","kind":"exercise","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each  Performance Stock Unit (\"PSU\") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% will vest on August 31, 2018."}],"balance_after":222035,"source":{"system":"sec-edgar","filing":"0001209191-18-048736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118048736/doc4.xml","form_type":"4"}},{"id":3899789,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-06-08T18:18:45.000Z","date":"2018-06-06","kind":"sale","acquired":false,"shares":5113,"price":45.21,"value":231158.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 13, 2017, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.54, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote to this Form 4."}],"balance_after":222035,"source":{"system":"sec-edgar","filing":"0001209191-18-036768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118036768/doc4.xml","form_type":"4"}},{"id":3918419,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-05-24T20:22:46.000Z","date":"2018-05-22","kind":"tax_withholding","acquired":false,"shares":6491,"price":40.82,"value":264962.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":227148,"source":{"system":"sec-edgar","filing":"0001209191-18-033237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118033237/doc4.xml","form_type":"4"}},{"id":3918418,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-05-24T20:22:46.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":12890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Performance Stock Unit (\"PSU\") granted January 30, 2017 represented a contingent right to receive one share of Issuer's Common Stock. 12,890 PSUs became vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. 12,891 PSUs will vest on the first anniversary of the Certification Date."}],"balance_after":233639,"source":{"system":"sec-edgar","filing":"0001209191-18-033237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118033237/doc4.xml","form_type":"4"}},{"id":4010486,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-03-06T17:55:27.000Z","date":"2018-03-02","kind":"tax_withholding","acquired":false,"shares":19184,"price":32.53,"value":624055.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":70624,"source":{"system":"sec-edgar","filing":"0001209191-18-017424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118017424/doc4.xml","form_type":"4"}},{"id":4078928,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-02T20:15:10.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2018, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":100000,"derivative":{"exercise_price":51.31,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-18-007265","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118007265/doc4.xml","form_type":"4"}},{"id":4078927,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-02T20:15:10.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSU\") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-18-007265","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118007265/doc4.xml","form_type":"4"}},{"id":4229402,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-08-18T16:44:09.000Z","date":"2017-08-16","kind":"tax_withholding","acquired":false,"shares":7435,"price":54.86,"value":407884.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-049634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117049634/doc4.xml","form_type":"4"}},{"id":4270204,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-28","kind":"exercise","acquired":false,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":101820,"derivative":{"exercise_price":9,"exercise_date":"2010-07-14","expiration_date":"2020-07-14","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270203,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":69796,"derivative":{"exercise_price":9.8,"exercise_date":"2013-02-27","expiration_date":"2023-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270202,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":false,"shares":70014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":0,"derivative":{"exercise_price":7,"exercise_date":"2012-03-08","expiration_date":"2022-03-08","underlying":"Common Stock","underlying_shares":70014},"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270201,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":false,"shares":14285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":0,"derivative":{"exercise_price":7,"exercise_date":"2012-03-08","expiration_date":"2022-03-08","underlying":"Common Stock","underlying_shares":14285},"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270200,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":2070,"derivative":{"exercise_price":8.5,"exercise_date":"2011-03-23","expiration_date":"2021-03-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270199,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":false,"shares":95850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":115970,"derivative":{"exercise_price":9,"exercise_date":"2010-07-14","expiration_date":"2020-07-14","underlying":"Common Stock","underlying_shares":95850},"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270198,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-28","kind":"sale","acquired":false,"shares":14150,"price":55.35,"value":783202.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.68, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270197,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-28","kind":"exercise","acquired":true,"shares":14150,"price":9,"value":127350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":14150,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270196,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"sale","acquired":false,"shares":13100,"price":56.57,"value":741067.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.42 to $56.77, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270195,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"sale","acquired":false,"shares":112778,"price":55.9,"value":6304290.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.42 to $56.41, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":13100,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270194,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"sale","acquired":false,"shares":129271,"price":54.92,"value":7099563.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.41 to $55.41, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":125878,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270193,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":true,"shares":20000,"price":9.8,"value":196000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270192,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":true,"shares":70014,"price":7,"value":490098.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":70014,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270191,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":true,"shares":14285,"price":7,"value":99995.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":14285,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270190,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":true,"shares":55000,"price":8.5,"value":467500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4270189,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-06-29T20:15:31.000Z","date":"2017-06-27","kind":"exercise","acquired":true,"shares":95850,"price":9,"value":862650.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017."}],"balance_after":95850,"source":{"system":"sec-edgar","filing":"0001209191-17-042399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042399/doc4.xml","form_type":"4"}},{"id":4351981,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-04-14T18:44:17.000Z","date":"2017-04-11","kind":"sale","acquired":false,"shares":6750,"price":36.06,"value":243405.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This amendment is being filed for the purpose of providing a correction to footnote 1 of the original, which is now restated as footnote 2 to this filing."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 was effected for the purpose of tax withholding in connection with the vesting of Restricted Stock Units and was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2017 and amended on March 21, 2017."}],"balance_after":4730,"source":{"system":"sec-edgar","filing":"0001209191-17-027003","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117027003/doc4a.xml","form_type":"4/A","original_submission_date":"2017-04-11"}},{"id":4354360,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-04-11T16:34:29.000Z","date":"2017-04-11","kind":"sale","acquired":false,"shares":6750,"price":36.06,"value":243405.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2017."}],"balance_after":4730,"source":{"system":"sec-edgar","filing":"0001209191-17-026573","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117026573/doc4.xml","form_type":"4"}},{"id":4403294,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-03T17:37:51.000Z","date":"2017-03-02","kind":"tax_withholding","acquired":false,"shares":13669,"price":38.61,"value":527760.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":112839,"source":{"system":"sec-edgar","filing":"0001209191-17-017830","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117017830/doc4.xml","form_type":"4"}},{"id":4473364,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Unit","published_at":"2017-02-01T19:58:36.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":34375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the \"Certification Date\") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date.  If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the \"Certification Date\") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date.  If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest."}],"balance_after":34375,"derivative":{"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":34375},"source":{"system":"sec-edgar","filing":"0001209191-17-006889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117006889/doc4.xml","form_type":"4"}},{"id":4473363,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-01T19:58:36.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2017, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":137500,"derivative":{"exercise_price":25.54,"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":137500},"source":{"system":"sec-edgar","filing":"0001209191-17-006889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117006889/doc4.xml","form_type":"4"}},{"id":4473362,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-02-01T19:58:36.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":34375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSU\") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date."}],"balance_after":34375,"source":{"system":"sec-edgar","filing":"0001209191-17-006889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117006889/doc4.xml","form_type":"4"}}]}